Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Adenocarcinoma|Metastatic HER2-Positive Breast Carcinoma|Recurrent Breast Adenocarcinoma|Recurrent HER2-Positive Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Unresectable Breast Carcinoma|Unresectable HER2-Positive Breast Carcinoma
Interventions: DRUG: Atezolizumab|PROCEDURE: Biopsy|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Docetaxel|PROCEDURE: Magnetic Resonance Imaging|DRUG: Paclitaxel|BIOLOGICAL: Pertuzumab|OTHER: Placebo Administration|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Trastuzumab
Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology